Date: 7-8 June 2022

Venue:  Council of Europe, Avenue de l’Europe, 67075 Strasbourg, France

Working language: English



The COVID-19 pandemic and the emergence of mRNA vaccines have highlighted the importance of nanoparticle formulations – especially lipid-based systems – used for nucleic acid-based APIs. The success of SARS-CoV-2 vaccination programmes across the globe has demonstrated that these nanoparticle-based formulations can be used to produce safe and efficacious medicinal products.

Seen as part of a broader trend, modern formulations using nanoparticle systems (e.g. liposomes) have long been the focus of pharmaceutical research, and we are beginning to see the fruits of this with the emergence of new medicinal products based on these formulations. Consequently, attention is turning increasingly to issues surrounding the creation and implementation of standards for medicinal products using liposomes or other nanoparticle-based preparations.

The aim of this event is to identify any gaps and opportunities for standards concerning modern nanoparticle-based formulations which can be filled by the European Pharmacopoeia (Ph. Eur.), notably by setting common quality standards across Europe and beyond. This has particular relevance in the context of the COVID-19 pandemic.

The event is planned as an in-person event to be held at: Council of Europe, Avenue de l’Europe, 67075 Strasbourg, France

Programme Overview

Highlights of the programme include:

  • A general introduction comprising:
    • an overview of recent developments in the field of nanotechnologies;
    • an introduction to current Ph. Eur. activities.
  • A dedicated session on mRNA vaccines, addressing in particular manufacturing/CMC issues, CQAs and analytical methods for quality control and stability;
  • A session on other nanomedicines, highlighting analytical challenges and setting out the needs of stakeholders regarding standardisation;
  • A final brainstorming session on how the Ph. Eur. can fill any gaps identified during the event.

Participants will have the opportunity to interact directly with specialists in the field, discuss specific technicalities based on case studies and share their real-world experience.

Download the programme

Who should attend?

This event will be of interest to vaccine manufacturers, pharmaceutical manufacturers from other fields using nanotechnologies, specialist suppliers (including providers of raw materials) and representatives from national and international regulatory bodies. It will also be of particular interest to staff members and scientists involved in the quality control of nanomedicines, be it in R&D, manufacturing, regulatory affairs, quality assurance or any similar role in industry, regulatory authorities or sub-contracting laboratories.


The fee for this event is 200 EUR. The registration fee is due before the start of the event.

This fee includes all materials, lunches and refreshments. It does not include accommodation or travel expenses.



If you have any queries or experience any difficulties registering online, please email us via the EDQM HelpDesk.

Before registering, please read the Terms of Supply for EDQM Events.